抗Human TRAIL R4/TNFRSF10D PerCP抗体(Anti-Human TRAIL R4/TNFRSF10D PerCP antibody)

• 価格
• Product Details
• Applications and Data
• Related Product & Information

価格

目次に戻る

Product Details

Species Reactivity	Human
Label	PerCP (Peridinin-chlorophyll Protein Complex)
Immunogen	Mouse myeloma cell line NS0-derived recombinant human TRAIL R4/TNFRSF10D Ala56-His211Accession # Q9UBN6
Source	Monoclonal Mouse IgG1 Clone # 104918
Purification	Protein A or G purified from ascites
Specificity	Detects human TRAIL R4/TNFRSF10D in ELISAs and Western blots. In sandwich immunoassays, less than 5% cross-reactivity with recombinant human (rh) TRAIL R1, rhTRAIL R2, rhTRAIL R3, rhTRAIL, rhTNF‑ alpha, and rhTNF-beta is observed.

目次に戻る

Applications and Data

	Recommended Concentration	Sample
Flow Cytometry	10 µL/106 cells	See below

Flow Cytometry
	Detection of TRAIL R4/TNFRSF10D in Human Whole Blood Granulocytes by Flow Cytometry. Human whole blood granulocytes were stained with Mouse Anti-Human TRAIL R4/TNFRSF10D PerCP‑conjugated Monoclonal Antibody (Catalog # FAB633C, filled histogram) or isotype control antibody (Catalog # IC002C, open histogram). View our protocol for Staining Membrane-associated Proteins.

目次に戻る

Related Product & Information

Long Name	TRAIL Receptor 4
Background	TRAIL R4/TNFRSF10D
background_content	Background: TRAIL R4/TNFRSF10D TRAIL-R4, also known as TRAIL-R4 alpha, Decoy Receptor 2 (DcR2) and TNFRSF10D, is a 39-48 kDa member of the TNFR Superfamily of proteins. Mature TRAIL-R4/DcR2 is a type I transmembrane protein 331 amino acids (aa) in length. It contains a 156 aa extracellular domain (ECD) (aa 56-211), and a 154 aa cytoplasmic region that contains a truncated death domain. The presence of this truncation is not believed to allow for a positive signal for the initiation of apoptosis. This has led to its description as a "decoy receptor", suggesting that its function is to simply sequester and decrease the amount of TRAIL available for binding to the two apoptosis-inducing TRAIL receptors, DR4 and DR5. At this time, this view would appear to be unlikely, as it now seems that DcR2 actually complexes with DR5/TRAIL-R2, blocking the activation of Caspase-8, a first step in the initiation of apoptosis. In addition, in a ligand-dependent manner, the presence of DcR2 has also been associated with the increased survival of select leukocytes. Notably, an isoform variant for TRAIL-R4 (called TRAIL-R4 beta ) has been reported that shows an absence of aa 87-124, a deletion that would render it incapable of binding to TRAIL. Cells reported to express TRAIL-R4 are varied, and include eosinophils, NKT cells, CD8+ (but not CD4+) T cells, colonic columnar epithelium, neutrophils, endometrial columnar epithelium, testicular spermatids and testosterone-secreting Leydig cells, and multiple tumor cell types. A rodent counterpart to TRAIL-R4 has not been reported.

目次に戻る